FDA Issues Warning Statement About Contaminated Illegal Synthetic Cannabinoid Products
The FDA released a statement this week about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum.
The U.S. Food and Drug Administration (FDA) released a statement this week (1) about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum, a very long-acting anticoagulant commonly used in rat poison. According to the statement, these unapproved products are being sold in convenience stores and gas stations as substitutes for cannabis under names such as “K2” and “Spice.”
The statement came from Commissioner Scott Gottlieb, MD, Peter Marks, MD, PhD, who is the director for the Center for Biologics Evaluation and Research, and Janet Woodcock, MD, who is the director of the Center for Drug Evaluation and Research. They stressed that the presence of brodifacoum in these illegal and unregulated products poses severe health risks because it can cause severe bleeding. They also explained that in recent months, hundreds of individuals in about 10 states (many in the Midwest) have been hospitalized after experiencing such complications.
“Today, we’re joining together to send a strong warning to anyone who may use synthetic marijuana products that these products can be especially dangerous as a result of the seemingly deliberate use of brodifacoum in these illegal products,” they said in the statement.
The statement also stressed that the use of these illegal products poses significant public health concerns for both individuals who use them and the U.S. blood supply because there is the potential for contamination of blood products donated by those individuals who have used these substances...
For more information, please read the full press release.
References:
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
